



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: 4-[(1S)-1-[[5-氯-2-(4-氟苯氧基)苄基]氨基]乙基]苯甲酸
产品别名: CJ-42794

生物活性:																					
Description	CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3). IC50 value: 8.5 (pKi) [1] Target: EP4 in vitro: CJ-042794 competitively inhibits PGE2-evoked elevations of intracellular cAMP levels in HEK293 cells overexpressing human EP4receptor with a mean pA2 value of 8.6. PGE2 inhibits the lipopolysaccharide (LPS)-induced production of tumor necrosis factor α (TNF α) in human whole blood (HWPB); CJ-042794 reverses the inhibitory effects of PGE2 on LPS-induced TNF α production in a concentration-dependent manner. [1] in vivo: CJ-42794 significantly delays the ulcer healing in rats and mice. The expression of VEGF in primary rat gastric fibroblasts was increased by PGE2 or AE1-329 (EP4 agonist), and these responses were both attenuated by coadministration of CJ-42794.[2]																				
	In Vitro: DMSO : ≥ 28 mg/mL (67.66 mM) H₂O : < 0.1 mg/mL (insoluble) * "$\geq$" means soluble, but saturation unknown. <table><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent Concentration</th><th>Mass 1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>1 mM</th><td>2.4165 mL</td><td>12.0823 mL</td><td>24.1645 mL</td></tr><tr><th rowspan="2"></th><th>5 mM</th><td>0.4833 mL</td><td>2.4165 mL</td><td>4.8329 mL</td></tr><tr><th>10 mM</th><td>0.2416 mL</td><td>1.2082 mL</td><td>2.4165 mL</td></tr></table> *请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80℃，6 months；-20℃，1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.5 mg/mL (6.04 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (6.04 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。 2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (6.04 mM); Suspended solution; Need ultrasonic				Preparing Stock Solutions	Solvent Concentration	Mass 1 mg	5 mg	10 mg	1 mM	2.4165 mL	12.0823 mL	24.1645 mL		5 mM	0.4833 mL	2.4165 mL	4.8329 mL	10 mM	0.2416 mL	1.2082 mL
Preparing Stock Solutions	Solvent Concentration	Mass 1 mg	5 mg	10 mg																	
	1 mM	2.4165 mL	12.0823 mL	24.1645 mL																	
	5 mM	0.4833 mL	2.4165 mL	4.8329 mL																	
	10 mM	0.2416 mL	1.2082 mL	2.4165 mL																	



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

	此方案可获得 2.5 mg/mL (6.04 mM)的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水溶液中，混合均匀。 3.请依序添加每种溶剂： 10% DMSO $\rightarrow$90% corn oil Solubility: $\geq$ 2.5 mg/mL (6.04 mM); Clear solution 此方案可获得 $\geq$ 2.5 mg/mL (6.04 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。
References	[1]. Murase A, et al. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci. 2008 Jan 16;82(3-4):226-232. [2]. Hatazawa R, et al. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol Gastrointest Liver Physiol. 2007 Oct;293(4):G788-97.

源叶生物